231 related articles for article (PubMed ID: 16528141)
1. Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient.
Papadimitriou GN; Theleritis CG; Dikeos DG; Psarros CJ; Soldatos CR
Int Clin Psychopharmacol; 2006 May; 21(3):181-4. PubMed ID: 16528141
[TBL] [Abstract][Full Text] [Related]
2. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
[TBL] [Abstract][Full Text] [Related]
3. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.
Müller MJ; Regenbogen B; Sachse J; Eich FX; Härtter S; Hiemke C
Pharmacopsychiatry; 2006 Mar; 39(2):41-6. PubMed ID: 16555163
[TBL] [Abstract][Full Text] [Related]
4. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics.
Lin CC; Bai YM; Wang YC; Chen TT; Lai IC; Chen JY; Chen SY; Gau SS; Liou YJ
J Clin Psychopharmacol; 2009 Dec; 29(6):529-36. PubMed ID: 19910716
[TBL] [Abstract][Full Text] [Related]
5. THE LESSA (Lebanese Short-term Study with Amisulpride) STUDY a Phase IV clinical trial in acutely ill schizophrenic patients.
Baddoura R; Ourgandjian H
J Med Liban; 2004; 52(2):78-85. PubMed ID: 15884686
[TBL] [Abstract][Full Text] [Related]
6. Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study.
Rettenbacher MA; Hummer M; Hofer A; Baumgartner S; Ebenbichler C; Edlinger M; Kemmler G; Lechleitner M; Wolfgang Fleischhacker W
J Psychopharmacol; 2007 Jun; 21(4):400-4. PubMed ID: 17050656
[TBL] [Abstract][Full Text] [Related]
7. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.
Linden M; Scheel T; Eich FX
J Psychopharmacol; 2006 Nov; 20(6):815-23. PubMed ID: 16401647
[TBL] [Abstract][Full Text] [Related]
8. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.
Surguladze S; Patel A; Kerwin RW; Knapp M; Travis MJ
Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):517-22. PubMed ID: 15866352
[TBL] [Abstract][Full Text] [Related]
9. Effects of second generation antipsychotics on leptin and ghrelin.
Esen-Danaci A; Sarandöl A; Taneli F; Yurtsever F; Ozlen N
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1434-8. PubMed ID: 18579280
[TBL] [Abstract][Full Text] [Related]
10. Plasma amisulpride levels in schizophrenia or schizoaffective disorder.
Bergemann N; Kopitz J; Kress KR; Frick A
Eur Neuropsychopharmacol; 2004 May; 14(3):245-50. PubMed ID: 15056484
[TBL] [Abstract][Full Text] [Related]
11. The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.
Herrera-Estrella M; Apiquian R; Fresan A; Sanchez-Torres I
BMC Psychiatry; 2005 May; 5():22. PubMed ID: 15869707
[TBL] [Abstract][Full Text] [Related]
12. Amisulpride--an open clinical study of a new benzamide in schizophrenic patients.
Mann K; Bartels M; Bauer H; Gaertner HJ
Pharmacopsychiatry; 1984 Jul; 17(4):111-5. PubMed ID: 6147865
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study.
Molina JD; Lerma-Carrillo I; Leonor M; Pascual F; Blasco-Fontecilla H; González-Parra S; López-Muñoz F; Alamo C
Clin Neuropharmacol; 2009; 32(1):10-5. PubMed ID: 18978498
[TBL] [Abstract][Full Text] [Related]
14. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia.
Cook B; Hoogenboom G
Australas Psychiatry; 2004 Mar; 12(1):74-6. PubMed ID: 15715745
[TBL] [Abstract][Full Text] [Related]
15. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
Kim EY; Kim SH; Lee NY; Jung DC; Kim YS; Ahn YM
Pharmacopsychiatry; 2012 Mar; 45(2):57-63. PubMed ID: 22411694
[TBL] [Abstract][Full Text] [Related]
16. How do we choose between atypical antipsychotics? The advantages of amisulpride.
Mortimer AM
Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S21-5. PubMed ID: 14972081
[TBL] [Abstract][Full Text] [Related]
17. Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls.
Ahn YM; Lee KY; Kim CE; Kim JJ; Kang DY; Jun TY; Choi JS; Chung IW; Kim SH; Hwang SS; Kim YS
J Clin Psychopharmacol; 2009 Apr; 29(2):117-23. PubMed ID: 19512972
[TBL] [Abstract][Full Text] [Related]
18. Weight change with atypical antipsychotics in the treatment of schizophrenia.
Haddad P
J Psychopharmacol; 2005 Nov; 19(6 Suppl):16-27. PubMed ID: 16280334
[TBL] [Abstract][Full Text] [Related]
19. Amisulpride related tic-like symptoms in an adolescent schizophrenic.
Lin CL; Shiah IS; Yeh CB; Wan FJ; Wang TS
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):144-6. PubMed ID: 16225977
[TBL] [Abstract][Full Text] [Related]
20. Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study.
Hrdlicka M; Zedkova I; Blatny M; Urbanek T
Neuro Endocrinol Lett; 2009; 30(2):256-61. PubMed ID: 19675512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
